Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Cripto-1 Represents a Biomarker for Chronic Inflammatory Diseases

Posted Jun 30 2008 5:00pm

Description of Invention:
Chronic inflammatory bowel disease (IBD) (e.g. Crohn’s disease and ulcerative colitis) and chronic inflammatory arthropathy such as rheumatoid arthritis represent an enormous socio-economic burden due to the cost for long term medication and rehabilitation and the decreased productivity due to periods of acute recurrences. A major characteristic of these diseases is the tissue infiltration of specific CD4+ T cells that sustain inflammation by secreting cytokines. One of these cytokines, TNF-alpha, is a current therapeutic target for the treatment of these chronic inflammatory diseases.

This technology describes Cripto-1 as a biomarker for chronic inflammatory diseases. Cripto-1, an epidermal growth factor (EGF)-related protein, shows higher expression levels in tissue sections of Crohn’s disease, ulcerative colitis, and rheumatoid arthritis as compared to adjacent unaffected areas. Moreover, the inventors show that the response to Cripto-1 is not due to a generic immune response, and Cripto-1 expression increases the expression of TNF-alpha in CD4+ T cells in tissues affected by chronic inflammatory disease. As a result, this technology could be used as a diagnostic biomarker for chronic inflammatory diseases as well as a novel therapeutic target to help control TNF-alpha in chronic inflammatory diseases.

Applications:
  • Diagnostic tool for the detection of a chronic inflammatory disease.
  • Method to inhibit cytokine production in a tissue affected with a chronic inflammatory disease.


Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Luigi Strizzi (NCI)
David S Salomon (NCI)
Monica I Gonzales (NCI)


Patent Status:
HHS, Reference No. E-075-2008/0
PCT, Application No. PCT/US09/40980 filed 17 Apr 2009


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute Mammary Biology and Tumorigenesis Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Cripto-1 as a biomarker for chronic inflammatory diseases. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Internal Medicine
Internal Medicine - Diagnostics



For Additional Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220


Ref No: 1775

Updated: 07/2008

Post a comment
Write a comment:

Related Searches